From the top colorectal cancer screening test on the market, to drug screens and urinalysis, Pinnacle's Home Use tests are tax free and ship free in the United States.  Click on an image to learn more.  Questions on how to use a product?  Call us at 1-800-609-6419

Learn more about how Pinnacle BioLabs is changing the outcome of colorectal cancer with it's patented Quantum Remote Read Store and 4ward technology, which is achieving  90+ percent compliance in mass colorectal cancer screening campaigns at 1/8 of the cost of the current automated fecal occult blood testing modalities.  


Statistics in Opioid Use: Why medication monitoring is important

September 06, 2014

According to the International Association for the Study of Pain, chronic pain generally refers to pain that “persists beyond normal tissue healing time, which is assumed to be three months.” 1 The statistics on the prevalence of chronic pain and the pervasive inappropriate use of pain medication make an overwhelming case for pain medication monitoring as a part of effective patient and medication management. One in four Americans suffers from chronic pain.2 Chronic noncancer pain (CNCP) is a leading cause of disability.3,4 For many patients, opioids are an integral part of a comprehensive pain management plan to help relieve pain, restore functioning and improve quality of life.5 Through point of care drug testing, one national study found that many pain patients may not be taking... Continue Reading →

Fecal Immunochemical Test the most cost effective approach to population based screening for colorectal cancer

August 30, 2014

FIT test Vs. Colonoscopy as a screening tool for Colorectal Cancer:  A cost comparative study A new study comparing colonoscopy, FIT (fecal immunochemical test) testing, Stool DNA testing, flex sig, and guaiac card testing finds that the FIT test is the most cost effective test for population based screening of asymptomatic patients for colon and rectal (CRC) cancers.   Methods and Findings An incremental cost-utility analysis using a Markov model was performed comparing guaiac-based fecal occult blood test (FOBT) or fecal immunochemical test (FIT) annually, fecal DNA every 3 years, flexible sigmoidoscopy or computed tomographic colonography every 5 years, and colonoscopy every 10 years. All strategies were also compared to a no screening natural history arm. Given that different FIT... Continue Reading →